Company profile for Mabwell

Mabwell

NEW Drugs in Dev.: 26

Evonik

Contact Supplier

AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

Contact Supplier

pharmacompass-1-m-2026-01-12

Contact Supplier

End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

Contact Supplier

Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

Contact Supplier

pharmacompass-2-m-2025-11-03

Contact Supplier

VISIT THE VIRTUAL BOOTH
Review portfolio & marketing content
CONTACT DETAILS
Google Map, LinkedIn, Emails...

DIGITAL CONTENT

59 News #PharmaBuzz

media
59 News #PharmaBuzz

DEVELOPMENTS

86 Drugs in Development

86 Drugs in Development

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Mabwell (688062.SH), an innovation-driven biopharmaceutical company, has the whole industrial chain of R&D, manufacturing, and commercialization. We provide more effective and accessible therapy and innovative medicines to fulfill global medical needs. Since 2017, an advanced R&D system which covers target discovery, early discovery, druggability, preclinical, clinical research and manufacturing transformation was established....

Mabwell (688062.SH), an innovation-driven biopharmaceutical company, has the whole industrial chain of R&D, manufacturing, and commercialization. We provide more effective and accessible therapy and innovative medicines to fulfill global medical needs. Since 2017, an advanced R&D system which covers target discovery, early discovery, druggability, preclinical, clinical research and manufacturing transformation was established. Mabwell has 14 pipeline products in different R&D stages based on a world-class and state-of-the-art R&D engine, including 10 novel drug candidates and 4 biosimilars.

Tides AsiaTides Asia

Not Confirmed

Not Confirmed

24-26 February, 2026

Tokyo, Japan
BIO Partnering at JPMBIO Partnering at JPM

Not Confirmed

Not Confirmed

12-15 January, 2026

San Francisco Marriott Marquis, California
Biotech ShowcaseBiotech Showcase

Not Confirmed

Not Confirmed

12-14 January, 2026

San Diego, California, U.S.A

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown

Country

Country

China

Address

Address

Building 3, Creative Park, No. 576 Libing Road, Pudong New Area, Shanghai

Telephone

Telephone

021-58585793

Email

enquiries@pharmacompass.com

Client Website

Website

https://www.mabwell.com/

Linkedin

youtube

YouTube

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

Mabwell's Adalimumab Biosimilar Nod For Marketing in Indonesia

31 Dec 2025

// PR NEWSWIRE

Mabwell Initiates PhII Trial For Anti-Il-11 Antibody for Scarring

30 Dec 2025

// PR NEWSWIRE

Mabwell Recieve IND Cleared For Anti-St2 Antibody Phase IIa Study

24 Dec 2025

// PR NEWSWIRE

Mabwell Ships Denosumab Injection Overseas For First Time

16 Dec 2025

// PR NEWSWIRE

Annualized Severe COPD Exacerbation Rate Reduced by Over 40%

01 Dec 2025

// PR NEWSWIRE

Mabwell Initiates First Dosing Of Cdh17-Targeting ADC 7MW4911

25 Nov 2025

// PR NEWSWIRE

Drugs in Development

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Privacy policy
Terms and conditions
Disclaimers
Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

Market Place

Home

Menu

Post Enquiry

Market Place

Search